H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer

H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer

Abstract Poly(ADP-ribose) polymerase (PARP) inhibitors represent a promising strategy toward the treatment of triple-negative breast cancer (TNBC), which is often associated to genomic instability and/or BRCA mutations. However, clinical outcome is controversial and no benefits have been demonstrate...

Full description

Bibliographic Details
Main Authors: S. Mazzucchelli, M. Truffi, F. Baccarini, M. Beretta, L. Sorrentino, M. Bellini, M. A. Rizzuto, R. Ottria, A. Ravelli, P. Ciuffreda, D. Prosperi, F. Corsi
Format: Article
Language:English
Published: Nature Publishing Group 2017-08-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-017-07617-7

Internet

https://doi.org/10.1038/s41598-017-07617-7

Similar Items